Reply to 'NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3'
Nat Rev Clin Oncol
.
2024 Dec;21(12):902.
doi: 10.1038/s41571-024-00953-4.
Authors
Christopher Nevala-Plagemann
1
,
Thierry Conroy
2
3
,
Ignacio Garrido-Laguna
4
Affiliations
1
Division of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
2
Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France.
3
Inserm INSPIIRE, Université de Lorraine, Nancy, France.
4
Division of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Ignacio.Garrido-Laguna@hci.utah.edu.
PMID:
39455871
DOI:
10.1038/s41571-024-00953-4
No abstract available
Publication types
Letter